Convergence Pharmaceuticals announced an extremely successful Phase II study result for its NaV 1.7 sodium channel blocker.
Their minimum definition of success was 30% of patients showing improvement and the study confirmed that 70% of patients showed improvement for treatment of trigeminal neuralgia (severe facial pain):
http://www.reuters.com/article/2013/03/27/idUSnPreCFBG3a+13c+PRN20130327
This is very good news...